Advertisement

Antipsychotic drugs and the risk of recurrent venous thromboembolism: A prospective cohort study

Published:March 13, 2018DOI:https://doi.org/10.1016/j.ejim.2018.02.030

      Highlights

      • Antipsychotics may be a risk factor for first venous thromboembolism (VTE).
      • Impact of antipsychotics on the risk of recurrent VTE (rVTE) remains unknown.
      • In this cohort, we evaluated 736 patients of whom 61 were exposed to antipsychotics.
      • Antipsychotic users have an annual risk of rVTE of 12%.
      • Antipsychotic exposure was an independent risk factor for rVTE (HR 1.9, 95% CI 1.1–3.3).

      Abstract

      Background

      Numerous studies have suggested that antipsychotic drugs are associated with an increased risk for a first episode of venous thromboembolism (VTE). However, after anticoagulation discontinuation, the impact of antipsychotic drugs on the risk of recurrent VTE (rVTE) remains unknown.

      Objective

      To estimate the risk of rVTE in association with antipsychotic drugs.

      Methods

      Between May 2000 and December 2012, we included all consecutive patients with a first unprovoked symptomatic VTE and who discontinued anticoagulation. During follow-up, exposure to antipsychotic drugs was systematically assessed.

      Results

      A total of 736 patients with a first unprovoked symptomatic VTE were followed-up during a median period of 27.0 months (interquartile range (IQR) 6.2–60.0). Patients' median age was 66.0 years (IQR 49.0–76.0), 404 (54.9%) were men, and 61 (8.3%) were exposed to antipsychotics during follow-up. The incidence rate of r VTE was 12.1% person-year (95% CI 7.2–20.5) in antipsychotics users compared with 8.3% person-year (95% CI 7.1–9.8) in non-users (p = 0.20). Multivariate analysis showed a significant increased risk of recurrence associated with antipsychotic exposure (adjusted hazard ratio 1.9, 95% CI 1.1–3.3).

      Conclusions

      In this cohort study, exposure to antipsychotic drugs was found to be associated with an increased risk of rVTE among patients with a previous first unprovoked symptomatic VTE and who discontinued anticoagulation. Larger studies are needed to confirm and further explore this association.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Baglin T.
        • Luddington R.
        • Brown K.
        • Baglin C.
        Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilia risk factors: prospective cohort study.
        Lancet. 2003; 362: 523-526
        • Büller H.R.
        • Agnelli G.
        • Hull R.D.
        • Hyers T.M.
        • Prins M.H.
        • Raskob G.E.
        Antithrombotic therapy for venous thromboembolic disease: the seventh ACCP conference on antithrombotic and thrombolytic therapy.
        Chest. 2004; 126: 401S-428S
        • Agnelli G.
        • Prandoni P.
        • Santamaria M.G.
        • Bagatella P.
        • Iorio A.
        • Bazzan M.
        • et al.
        Warfarin optimal duration Italian trial investigators. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin optimal duration Italian trial investigators.
        N Engl J Med. 2001; 345: 165-169
        • Kearon C.
        • Gent M.
        • Hirsh J.
        • Weitz J.
        • Kovacs M.J.
        • Anderson D.R.
        • et al.
        A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism.
        N Engl J Med. 1999; 340: 901-907
        • Prandoni P.
        • Noventa F.
        • Ghirarduzzi A.
        • Pengo V.
        • Bernardi E.
        • Pesavento R.
        • et al.
        The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients.
        Haematologica. 2007; 92: 199-205
        • Ridker P.M.
        • Goldhaber S.Z.
        • Danielson E.
        • Rosenberg Y.
        • Eby C.S.
        • Deitcher S.R.
        • et al.
        Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.
        N Engl J Med. 2003; 348: 1425-1434
        • Eichinger S.
        • Hron G.
        • Bialonczyk C.
        • Hirschl M.
        • Minar E.
        • Wagner O.
        • et al.
        Overweight, obesity, and the risk of recurrent venous thromboembolism.
        Arch Intern Med. 2008; 168: 1678-1683
        • Kyrle P.A.
        • Minar E.
        • Bialonczyk C.
        • Hirschl M.
        • Weltermann A.
        • Eichinger S.
        The risk of recurrent venous thromboembolism in men and women.
        N Engl J Med. 2004; 350: 2558-2563
        • Zhang R.
        • Dong L.
        • Shao F.
        • Tan X.
        • Ying K.
        Antipsychotics and venous thromboembolism risk: a meta-analysis.
        Pharmacopsychiatry. 2011; 44: 183-188
        • Chapelle C.
        • Quenet S.
        • Delavenne X.
        • Lacut K.
        • Mismetti P.
        • Laporte S.
        • et al.
        Antipsychotics: a real or confounding risk factor for venous thromboembolism?.
        Pharmacopsychiatry. 2013; 46: 36-37
        • Hägg S.
        • Jönsson A.
        • Spigset O.
        Risk of venous thromboembolism due to antipsychotic drug therapy.
        Expert Opin Drug Saf. 2009; 8: 537-547
        • Delluc A.
        • Tromeur C.
        • Le Moigne E.
        • Nowak E.
        • Mottier D.
        • Le Gal G.
        • et al.
        Lipid lowering drugs and the risk of recurrent venous thromboembolism.
        Thromb Res. 2012; 130: 859-863
        • Prandoni P.
        • Lensing A.W.A.
        • Bernardi E.
        • Villalta S.
        • Bagatella P.
        • Girolami A.
        • et al.
        The diagnostic value of compression ultrasonography in patients with suspected recurrent deep vein thrombosis.
        Thromb Haemost. 2002; 88: 402-406
        • Plu-Bureau G.
        • Maitrot-Mantelet L.
        • Hugon-Rodin J.
        • Canonico M.
        Hormonal contraceptives and venous thromboembolism: an epidemiological update.
        Best Pract Res Clin Endocrinol Metab. 2013; 27: 25-34
        • Christiansen S.C.
        • Lijfering W.M.
        • Helmerhorst F.M.
        • Rosendaal F.R.
        • Cannegieter S.C.
        Sex difference in risk of recurrent venous thrombosis and the risk profile for a second event.
        J Thromb Haemost. 2010; 8: 2159-2168
        • Eischer L.
        • Eichinger S.
        • Kyrle P.A.
        The risk of recurrence in women with venous thromboembolism while using estrogens: a prospective cohort study.
        J Thromb Haemost. 2014; 12: 635-640
        • Cushman M.
        • Glynn R.J.
        • Goldhaber S.Z.
        • Moll S.
        • Bauer K.A.
        • Deitcher S.
        • et al.
        Hormonal factors and risk of recurrent venous thrombosis: the prevention of recurrent venous thromboembolism trial.
        J Thromb Haemost. 2006; 4: 2199-2203
        • Leucht S.
        • Cipriani A.
        • Spineli L.
        • Mavridis D.
        • Orey D.
        • Richter F.
        • et al.
        Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.
        Lancet. 2013; 382: 951-962
        • Furukawa T.A.
        • Levine S.Z.
        • Tanaka SGoldberg Y.
        • Samara M.
        • Davis J.M.
        • Cipriani A.
        • et al.
        Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies.
        JAMA Psychiat. 2015; 72: 14-21
        • Ishiguro C.
        • Wang X.
        • Li L.
        • Jick S.
        Antipsychotic drugs and risk of idiopathic venous thromboembolism: a nested case-control study using the CPRD.
        Pharmacoepidemiol Drug Saf. 2014; 23: 1168-1175
        • Kleijer B.C.
        • Heerdink E.R.
        • Egberts T.C.
        • Jansen P.A.
        • van Marum R.J.
        Antipsychotic drug use and the risk of venous thromboembolism in elderly patients.
        J Clin Psychopharmacol. 2010; 30: 526-530
        • Parker C.
        • Coupland C.
        • Hippisley-Cox J.
        Antipsychotic drugs and risk of venous thromboembolism: nested case–control study.
        BMJ. 2010; 341c4245